EXCLUSIVE: Longeveron's Heart Disease Cell Therapy Poised To Secure European Patent

The European Patent Office has issued a notice of its intent to grant Longeveron Inc LGVN a patent related to methods to treat endothelial dysfunction and monitor the efficacy of allogeneic mesenchymal cell therapies, also known as medicinal signaling cells (MSCs).

The patent is expected to expire in November of 2035. 

The cells are administered to patients with cardiovascular disease through monitoring the Vascular Endothelial Growth Factor, a signal protein produced by many cells that stimulate the formation of blood vessels.

Related: EXCLUSIVE: Longeveron Adds Miami Veterans Affairs Site To Its Ongoing Mid-Stage Alzheimer's Trial.

Longeveron's lead investigational product is Lomecel-B, a cell therapy product derived from MSCs. Many of Longeveron's clinical studies show Lomecel-B exerts effects through pro-vascular functions and/or reduces endothelial dysfunction, a condition where the lining of blood vessels is abnormal, leading to diminished health of blood vessels and blood flow regulation. 

The company is evaluating the use of MSCs to treat several indications, including Hypoplastic Left Heart Syndrome, a rare and life-threatening congenital heart defect. Longeveron is currently evaluating Lomecel-B in a Phase 2a trial.

Longeveron is also conducting a trial of Lomecel-B in patients with Alzheimer's disease in the U.S. and for aging frailty in Japan.

Price Action: LGVN shares closed 2.31% at $5.32 during after-hours trading on Wednesday.